Autologous stem cell transplantation is a viable postremission therapy for intermediate-risk acute myeloid leukemia in first complete remission in the absence of a …

Z Li, Y Liu, Q Wang, L Chen, L Ma, S Hao - Acta haematologica, 2019 - karger.com
Background: The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …
被引用次数：20 相关文章

Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of …

Z Li, Y Liu, Q Wang, L Chen, L Ma… - Acta …, 2019 - pubmed.ncbi.nlm.nih.gov
Background The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …
[HTML] nih.gov

[HTML][HTML] Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the …

Z Li, Y Liu, Q Wang, L Chen, L Ma, S Hao - Acta Haematologica, 2019 - ncbi.nlm.nih.gov
Background The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …
[HTML] karger.com

[HTML][HTML] Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the …

Z Li, Y Liu, Q Wang, L Chen, L Ma, S Hao - Acta Haematologica, 2019 - karger.com
Background: The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …

Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of …

Z Li, Y Liu, Q Wang, L Chen, L Ma, S Hao - Acta Haematologica, 2019 - europepmc.org
Background The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …

Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of …

Z Li, Y Liu, Q Wang, L Chen, L Ma… - Acta …, 2019 - search.ebscohost.com
Background: The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …

Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of …

Z Li, Y Liu, Q Wang, L Chen, L Ma… - Acta …, 2019 - search.ebscohost.com
Background: The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …

Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of …

Z Li, Y Liu, Q Wang, L Chen, L Ma, S Hao - Acta Haematologica, 2019 - europepmc.org
Background The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …